# Exozymes Inc.: financial statements, quarterly

EXOZ · Nasdaq · CIK 2010788 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/exoz.md) · [Financials](/companies/exoz/financials.md) · [Filings](/companies/exoz/filings.md) · [Insiders](/companies/exoz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/exoz/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | [(0.7) d](/filings/0001641172-25-001744.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [27.9](/filings/0001493152-24-044813.md) | [460 d](/filings/0001641172-25-001744.md) | [278](/filings/0001641172-25-009636.md) | [237](/filings/0001641172-25-023184.md) | [723](/filings/0001493152-25-022289.md) | [630 d](/filings/0001493152-26-013563.md) | [575](/filings/0001493152-26-023035.md) | [803](/filings/0001493152-26-037725.md) | [1,217](/filings/0001493152-25-022289.md) | [1,112 d](/filings/0001493152-26-013563.md) | [1,121](/filings/0001493152-26-023035.md) | [1,438](/filings/0001493152-26-037725.md) |
| Operating income | $k | [(392)](/filings/0001493152-24-044813.md) | [(985) d](/filings/0001641172-25-001744.md) | [(1,008)](/filings/0001641172-25-009636.md) | [(1,329)](/filings/0001641172-25-023184.md) | [(1,612)](/filings/0001493152-25-022289.md) | [(1,983) d](/filings/0001493152-26-013563.md) | [(1,951)](/filings/0001493152-26-023035.md) | [(2,548)](/filings/0001493152-26-037725.md) | [(2,522)](/filings/0001493152-25-022289.md) | [(2,695) d](/filings/0001493152-26-013563.md) | [(2,387)](/filings/0001493152-26-023035.md) | [(2,954)](/filings/0001493152-26-037725.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | [44.6](/filings/0001493152-24-044813.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | [2.1](/filings/0001641172-25-023184.md) | [(0.0) d](/filings/0001493152-25-022289.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(521)](/filings/0001493152-24-044813.md) | [(1,099) d](/filings/0001641172-25-001744.md) | [(1,008)](/filings/0001493152-25-022289.md) | [(1,361)](/filings/0001493152-25-022289.md) | [(1,656)](/filings/0001493152-25-022289.md) | [(1,836) d](/filings/0001493152-26-013563.md) | [(1,856)](/filings/0001493152-26-037725.md) | [(2,360)](/filings/0001493152-26-037725.md) | [(2,287)](/filings/0001493152-25-022289.md) | [(2,655) d](/filings/0001493152-26-013563.md) | [(2,370)](/filings/0001493152-26-037725.md) | [(2,879)](/filings/0001493152-26-037725.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001493152-24-044813.md) | not reported | [(0.16)](/filings/0001641172-25-009636.md) | [(0.22)](/filings/0001641172-25-023184.md) | [(0.27)](/filings/0001493152-25-022289.md) | not reported | [(0.22)](/filings/0001493152-26-023035.md) | [(0.28)](/filings/0001493152-26-037725.md) | [(0.27)](/filings/0001493152-25-022289.md) | not reported | [(0.28)](/filings/0001493152-26-023035.md) | [(0.33)](/filings/0001493152-26-037725.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001493152-24-044813.md) | not reported | [(0.16)](/filings/0001641172-25-009636.md) | [(0.22)](/filings/0001641172-25-023184.md) | [(0.27)](/filings/0001493152-25-022289.md) | not reported | [(0.22)](/filings/0001493152-26-023035.md) | [(0.28)](/filings/0001493152-26-037725.md) | [(0.27)](/filings/0001493152-25-022289.md) | not reported | [(0.28)](/filings/0001493152-26-023035.md) | [(0.33)](/filings/0001493152-26-037725.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.1](/filings/0001641172-25-001744.md) | not reported | not reported | [0.2](/filings/0001493152-24-044813.md) | [9.7](/filings/0001493152-26-013563.md) | [8.5](/filings/0001641172-25-009636.md) | [7.0](/filings/0001641172-25-023184.md) | [5.1](/filings/0001493152-25-022289.md) | [3.0](/filings/0001493152-26-037725.md) | [1.4](/filings/0001493152-26-023035.md) | [5.7](/filings/0001493152-26-037725.md) |
| Current assets | $m | not reported | [1.2](/filings/0001641172-25-001744.md) | not reported | not reported | [1.4](/filings/0001493152-24-044813.md) | [10.8](/filings/0001493152-26-013563.md) | [9.4](/filings/0001641172-25-009636.md) | [7.5](/filings/0001641172-25-023184.md) | [5.6](/filings/0001493152-25-022289.md) | [3.9](/filings/0001493152-26-037725.md) | [2.1](/filings/0001493152-26-023035.md) | [6.2](/filings/0001493152-26-037725.md) |
| Total assets | $m | not reported | [3.6](/filings/0001641172-25-001744.md) | not reported | not reported | [3.6](/filings/0001493152-24-044813.md) | [13.0](/filings/0001493152-26-013563.md) | [11.5](/filings/0001641172-25-009636.md) | [9.7](/filings/0001641172-25-023184.md) | [7.7](/filings/0001493152-25-022289.md) | [6.0](/filings/0001493152-26-037725.md) | [4.0](/filings/0001493152-26-023035.md) | [8.0](/filings/0001493152-26-037725.md) |
| Current liabilities | $m | not reported | [2.4](/filings/0001641172-25-001744.md) | not reported | not reported | [5.8](/filings/0001493152-24-044813.md) | [1.3](/filings/0001493152-26-013563.md) | [1.4](/filings/0001641172-25-009636.md) | [1.2](/filings/0001641172-25-023184.md) | [1.2](/filings/0001493152-25-022289.md) | [1.6](/filings/0001493152-26-037725.md) | [1.6](/filings/0001493152-26-023035.md) | [1.6](/filings/0001493152-26-037725.md) |
| Total liabilities | $m | not reported | [3.9](/filings/0001641172-25-001744.md) | not reported | not reported | [7.2](/filings/0001493152-24-044813.md) | [2.6](/filings/0001493152-26-013563.md) | [2.6](/filings/0001641172-25-009636.md) | [2.4](/filings/0001641172-25-023184.md) | [2.3](/filings/0001493152-25-022289.md) | [2.6](/filings/0001493152-26-037725.md) | [2.5](/filings/0001493152-26-023035.md) | [4.3](/filings/0001493152-26-037725.md) |
| Shareholders' equity | $m | [0.6](/filings/0001493152-24-044813.md) | [(0.4)](/filings/0001493152-26-013563.md) | [(1.2)](/filings/0001493152-25-022289.md) | [(2.3)](/filings/0001493152-25-022289.md) | [(3.6)](/filings/0001493152-25-022289.md) | [10.4](/filings/0001493152-26-037725.md) | [8.9](/filings/0001493152-26-037725.md) | [7.2](/filings/0001493152-26-037725.md) | [5.4](/filings/0001493152-25-022289.md) | [3.4](/filings/0001493152-26-037725.md) | [1.5](/filings/0001493152-26-037725.md) | [3.7](/filings/0001493152-26-037725.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(783) d](/filings/0001641172-25-001744.md) | [281](/filings/0001641172-25-009636.md) | [(2,538) d](/filings/0001641172-25-023184.md) | [(542) d](/filings/0001493152-25-022289.md) | [(5,708) d](/filings/0001493152-26-013563.md) | [(1,134)](/filings/0001493152-26-023035.md) | [(1,538) d](/filings/0001493152-26-037725.md) | [(1,857) d](/filings/0001493152-25-022289.md) | [(1,974) d](/filings/0001493152-26-013563.md) | [(1,524)](/filings/0001493152-26-023035.md) | [(1,640) d](/filings/0001493152-26-037725.md) |
| Capital expenditure | $k | [110 d](/filings/0001641172-25-001744.md) | [149](/filings/0001641172-25-009636.md) | [37.2 d](/filings/0001641172-25-023184.md) | [0.0 d](/filings/0001493152-25-022289.md) | [210 d](/filings/0001493152-26-013563.md) | [31.0](/filings/0001493152-26-023035.md) | [50.6 d](/filings/0001493152-26-037725.md) | [13.3 d](/filings/0001493152-25-022289.md) | [75.0 d](/filings/0001493152-26-013563.md) | [57.6](/filings/0001493152-26-023035.md) | [(0.0) d](/filings/0001493152-26-037725.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [6,250](/filings/0001493152-24-044813.md) | [6,250](/filings/0001641172-25-009636.md) | [6,251](/filings/0001641172-25-023184.md) | [6,252](/filings/0001493152-25-022289.md) | [8,368](/filings/0001493152-26-023035.md) | [8,377](/filings/0001493152-26-037725.md) | [8,387](/filings/0001493152-25-022289.md) | [8,459](/filings/0001493152-26-023035.md) | [8,660](/filings/0001493152-26-037725.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,281,359 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037725.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.